Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis

Hepatology

Volumn 35, Issue 4, 2002, Pages 883-889

  Huang, Yi Shin ^a   Chern, Herng Der ^a   Su, Wei Juin ^b   Wu, Jaw Ching ^a   Lai, Shinn Liang ^b   Yang, Shi Yi ^a   Chang, Full Young ^a   Lee, Shou Dong ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG ACETYLATION; FEMALE; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROVOCATION TEST; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TOXIC HEPATITIS; TUBERCULOSIS;

EID: 0036202380     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2002.32102     Document Type: Article

References (42)

1. Drug-induced hepatotoxicity
2. Drug-induced acute hepatitis
3. Isoniazid-associated hepatitis in 114 patients
4. Increased incidence of isoniazid hepatitis in rapid acetylators: Possible relation to hydrazine metabolites
5. Isoniazid liver injury: Clinical spectrum, pathology and probable pathogenesis
6. Isoniazid-related hepatitis: A US public health service cooperative surveillance study
7. Predisposing factors in hepatitis induced by isoniazid-rifampicin treatment of tuberculosis
8. Toxic effects of isoniazid in tuberculosis chemoprophylaxis: Role of biochemical monitoring in 1, 000 patients
9. Risk factors for isoniazid (INH)-induced liver dysfunction
10. Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand south Indian patients during treatment with isoniazid for tuberculosis
11. Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype
12. Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampicin
13. Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide
14. Isoniazid-rifampicin-induced hepatitis in hepatitis B carriers
15. Retrospective survey of drug-induced liver disease at Groot Schuur Hospital, Cape Town - 1983-1987
16. Anti-tuberculosis medication and the liver: Dangers and recommendations in management
17. Risk factors for hepatotoxicity from antituberculosis drugs: A case-control study
18. A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B
19. Characterization of a major form of rat hepatic microsomal cytochrome P-450 induced by isoniazid
20. Pharmacokinetics of the toxic hydrazine metabolites formed from isoniazid in humans
21. Pharmacokinetics of isoniazid metabolism in man
22. Ethanol-induced increase in drug acetylation in man and isolated rat liver cells
23. Misclassification of genetic susceptibility biomarkers: Implications for case-control studies and cross-population comparisons
24. Correlation between N-acetyltransferase activity and NAT2 genotype in Chinese males
25. Pharmacogenetics in pediatrics. Implications for practice
26. Genotyping of the arylamine N-acetyltransferase polymorphism in the prediction of idiosyncratic reactions to trimethoprim-sulfamethoxazole in infants
27. Comparison of acetylation phenotype with genotype coding for N-acetyltransferase (NAT2) in children
28. Human arylamine N-acetyltransferase genes: Isolation, chromosomal localization and functional expression
29. Criteria of drug-induced liver disorders: Report of an international consensus meeting
30. Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries
31. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slowacetylator allele common in African-Americans
32. Drug-induced liver injury: Mechanisms and test systems
33. Mechanisms of drug-induced liver disease
34. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection
35. Genotype of N-acetyltransferase and isoniazid-rifampin-induced hepatitis in Chinese adults
36. Monoacetylhydrazine as a metabolite of isoniazid in man
37. Studies on hydrazine hepatotoxicity. 1. Pathological findings
38. Genetic predisposition to drug-induced liver disease
39. Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: Effects of 7 specific NAT2 nucleic acid substitutions
40. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene
41. Hepatic injury from the treatment of infectious and parasitic diseases